Leerink Partners Maintains Outperform on Benitec Biopharma, Raises Price Target to $18.27

Benzinga · 1d ago
Leerink Partners analyst Basma Radwan maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $18 to $18.27.